November 23, 2020
Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Piñeyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O’Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 Jan 11;39(1):38-53.e7. doi: 10.1016/j.ccell.2020.10.015. Epub 2020 Nov 19. PMID: 33217343; PMCID: PMC8478080.
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.
Declaration of Interests P.W.L. is a member of the Scientific Advisory Board for AnchorDX. H.S.’s husband is part of the Scientific Advisory Board for AnchorDX. N.D. is employed by Foundation Medicine and holds Roche stock. A.J. was an employee of and had ownership interest in Foundation Medicine. V.M. was an employee of and had ownership interest in Foundation Medicine (through 12/31/2019) and is an equity shareholder of Mirati Therapeutics, Inc; on the Board of Directors, compensated by and an equity shareholder of Revolution Medicines, Inc.; a part-time employee and equity shareholder of EqRx (since March 2020); and holds patents with the USPO: 8501413, 8067175 (held by Sloan-Kettering Institute for Cancer Research and licensed to Molecular MD). All other authors declare no competing interests.
Singapore Translational Cancer Consortium (STCC) has signed its first cross-border partnership with the Australian Victorian Cancer Biobank (VCB) to foster collaborations in translational oncology research. As part of the partnership agreement, STCC and VCB will share its oncology specimen databases, allowing researchers to access a wider array of tissue samples for cancer research. Both organisations will also share tissue banking best practices, and establish outreach programmes to advance clinical research collaborations between the two countries.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).